#johnson--johnson

#johnson--johnson

Johnson & Johnson's stock is popular due to its 3.3% dividend yield and positive performance despite recent healthcare market sell-offs.

Kenvue faces challenges in growth and profitability, leading to CEO resignation and strategic review after a 4% expected drop in net sales.

Johnson & Johnson has manipulated narratives to promote products, reflecting broader healthcare trust issues.

Dividend stocks are key for wealth building, offering income and reduced volatility, especially in uncertain economic conditions.

Investigative journalist Gardiner Harris critiques Johnson & Johnson's trustworthiness by linking its business practices to health crises, notably cancer from baby powder.